|
Market Closed -
Nasdaq
01:30:00 12/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 14.07 USD | -1.75% |
|
+1.66% | -10.27% |
Company Valuation: Monte Rosa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 949.7 | 368.3 | 282.8 | 426.4 | 1,021 | 1,200 | - | - |
| Change | - | -61.22% | -23.21% | 50.74% | 139.48% | 17.56% | - | - |
| Enterprise Value (EV) | 603.6 | 105.5 | 50.43 | 54.22 | 1,021 | 1,200 | 1,200 | 1,200 |
| Change | - | -82.52% | -52.19% | 7.5% | 1,783.24% | 17.56% | 0% | 0% |
| P/E | -6.9x | -3.31x | -2.15x | -7.08x | -34.1x | -9.36x | -7.42x | -8.45x |
| PBR | 2.75x | 1.32x | 1.58x | 1.91x | - | - | - | - |
| PEG | - | 0.1x | -0.1x | 0.1x | 0.6x | -0x | -0.3x | 0.7x |
| Capitalization / Revenue | - | - | - | 5.64x | 8.26x | 18.2x | 21x | 11.8x |
| EV / Revenue | - | - | - | 0x | 0x | 18.2x | 21x | 11.8x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -7.01x | -5.55x | -6.01x |
| EV / FCF | -0x | -0x | -0x | 0x | -0x | -14.3x | -17.2x | 38.4x |
| FCF Yield | -7.28% | -28.6% | -22.2% | 8.91% | -2.69% | -7.01% | -5.83% | 2.61% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | -1.504 | -1.896 | -1.665 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 75.62 | 123.7 | 65.89 | 57.07 | 101.9 |
| EBITDA | -70.75 | -108.6 | -137.1 | -72.99 | - | - | - | - |
| EBIT 1 | -72.88 | -112.4 | -143.3 | -81.11 | -54.21 | -171.2 | -216.4 | -199.7 |
| Net income 1 | -73.96 | -108.5 | -135.4 | -72.7 | -38.63 | -151.9 | -201.2 | -188.3 |
| Net Debt | -346.1 | -262.8 | -232.4 | -372.1 | - | - | - | - |
| Reference price 2 | 20.42 | 7.61 | 5.65 | 6.94 | 15.68 | 14.07 | 14.07 | 14.07 |
| Nbr of stocks (in thousands) | 46,506 | 48,399 | 50,062 | 61,436 | 65,118 | 85,313 | - | - |
| Announcement Date | 29/03/22 | 16/03/23 | 14/03/24 | 20/03/25 | 17/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.36x | - | - | - | 120.04Cr | |
| 31.04x | 5.6x | 16.76x | 1.05% | 4.55TCr | |
| -20.85x | 240.83x | -22.36x | -.--% | 4.37TCr | |
| 33.71x | 3.27x | 14.1x | -.--% | 4.31TCr | |
| 45.39x | 5.23x | 28.64x | -.--% | 3.94TCr | |
| 27.03x | 8.15x | 20.66x | 0.42% | 3.19TCr | |
| 33.41x | 5.47x | 24.85x | -.--% | 1.64TCr | |
| 23.57x | 2.06x | 8.94x | 1.13% | 1.42TCr | |
| 74.44x | 3.94x | 15.27x | -.--% | 1.33TCr | |
| Average | 26.49x | 34.32x | 13.36x | 0.33% | 2.76TCr | |
| Weighted average by Cap. | 26.00x | 46.68x | 11.79x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GLUE Stock
- Valuation Monte Rosa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
